Technical Analysis for NXTC - NextCure, Inc.

Grade Last Price % Change Price Change
grade B 19.9 1.69% 0.33
NXTC closed up 1.69 percent on Friday, May 24, 2019, on 32 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical NXTC trend table...

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
Multiple of Ten Bearish Other 1.69%
Down 3 Days in a Row Weakness 1.69%
Hot IPO Pullback Bullish Swing Setup 0.10%
Multiple of Ten Bearish Other 0.10%
Multiple of Ten Bullish Other -0.55%
Inside Day Range Contraction -0.55%
New 52 Week Closing High Bullish -3.59%
Multiple of Ten Bullish Other -3.59%

Older signals for NXTC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Medicine Health Biopharmaceutical Cancer Clinical Medicine Immunotherapy Cancer Treatments Virotherapy Non Small Cell Lung Cancer Tumor Ovarian Cancer Treatment Of Ovarian Cancer Oncolytics Biotech Metastasis Metastatic Solid Tumors Halozyme Immune Related Diseases Yale University
Is NXTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.75
52 Week Low 15.08
Average Volume 109,704
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 19.887
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0034
MACD Signal Line 0.0007
MACD Histogram 0.0027
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.93
Resistance 3 (R3) 22.01 21.40 21.59
Resistance 2 (R2) 21.40 20.89 21.37 21.48
Resistance 1 (R1) 20.65 20.57 21.03 20.58 21.37
Pivot Point 20.05 20.05 20.24 20.01 20.05
Support 1 (S1) 19.30 19.53 19.67 19.22 18.43
Support 2 (S2) 18.69 19.21 18.66 18.32
Support 3 (S3) 17.94 18.69 18.21
Support 4 (S4) 17.87